Apellis insider plans Rule 144 sale of 5,780 shares

Apellis Pharmaceuticals insider David O. Watson filed a notice of proposed sale of 5,780 common shares under Rule 144.

Rhea-AI Filing Summary

Apellis Pharmaceuticals insider David O. Watson filed a notice of proposed sale of 5,780 common shares under Rule 144. The shares are expected to be sold through Fidelity Brokerage Services on NASDAQ around 01/13/2026, with an indicated aggregate market value of 128,242.01. The filing notes that 126,525,218 common shares were outstanding.

The 5,780 shares were acquired on 01/12/2026 through restricted stock vesting from the issuer as compensation. The notice also lists prior sales by Watson over the past three months, including three separate sales of 5,000 common shares each on 10/16/2025, 11/17/2025, and 12/16/2025 with gross proceeds of 126,100.00, 100,300.00, and 122,450.00, respectively.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for Apellis (APLS) disclose?

It discloses that David O. Watson plans to sell 5,780 Apellis common shares under Rule 144, to be executed through Fidelity Brokerage Services on NASDAQ around 01/13/2026.

How many Apellis (APLS) shares are covered by this planned Rule 144 sale?

The notice covers a proposed sale of 5,780 shares of Apellis common stock, with an indicated aggregate market value of 128,242.01.

How did David O. Watson acquire the 5,780 Apellis (APLS) shares to be sold?

The 5,780 shares were acquired on 01/12/2026 via restricted stock vesting from the issuer, classified as compensation.

What were recent Apellis (APLS) share sales by David O. Watson before this notice?

Over the prior three months, Watson sold 5,000 Apellis common shares on each of 10/16/2025, 11/17/2025, and 12/16/2025, for gross proceeds of 126,100.00, 100,300.00, and 122,450.00, respectively.

How many Apellis (APLS) common shares were outstanding according to the Form 144?

The filing states that there were 126,525,218 Apellis common shares outstanding at the time referenced.

Which broker and exchange are used for the planned Apellis (APLS) share sale?

The proposed sale is through Fidelity Brokerage Services LLC, with the shares to be sold on the NASDAQ exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/13/2026 - 03:55 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001657719
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Apellis Pharmaceuticals, Inc.
SEC File Number	001-38276
Address of Issuer	100 FIFTH AVENUE WALTHAM MASSACHUSETTS 02451
Phone	617-977-5700
Name of Person for Whose Account the Securities are To Be Sold	Watson David O.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	5780	128242.01	126525218	01/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/12/2026	Restricted Stock Vesting	Issuer			5780	01/12/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David O. Watson 100 Fifth Avenue Waltham MA 02451	Common	10/16/2025	5000	126100.00
David O. Watson 100 Fifth Avenue Waltham MA 02451	Common	11/17/2025	5000	100300.00
David O. Watson 100 Fifth Avenue Waltham MA 02451	Common	12/16/2025	5000	122450.00

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	01/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for David O. Watson
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)